USA flag logo/image

An Official Website of the United States Government

Antiatherogenic Properties of tert-Butylhydroquinone

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70970
Program Year/Program:
2004 / STTR
Agency Tracking Number:
HL076925
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOINVENTIONS, LLC
3408 Berkshire Cir JOHNSON CITY, TN 37604-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Antiatherogenic Properties of tert-Butylhydroquinone
Agency: HHS
Contract: 1R41HL076925-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and triglycerides in a rat model. TBHQ is phenolic antioxidant commonly used as a food preservative. A patent, "Method for Reducing Blood Cholesterol and/or Blood Triglycerides," was subsequently obtained. The long-term objective of this research proposal is to determine the antiatherogenic potential of TBHQ and advance its commercial development. Our specific aims are to test the efficacy of TBHQ in: (1) reducing aortic atherosclerosis; (2) lowering plasma lipid levels; (3) promoting a less atherogenic lipoprotein profile and; (4) reducing plasma levels of C-reactive protein (CRP). Elevated levels of CRP are a risk factor for cardiovascular disease. In our phase I experiments, we will use the apoE knockout (apoE-/-) mouse model since it has been extensively used to study the antiatherogenic potential of other phenolic antioxidants. Our preliminary market analysis suggests that TBHQ could have a potential market of $100 million per year as a lipid-lowering agent. Commercial development should be accelerated since NIH has already conducted extensive toxicological studies with TBHQ.

Principal Investigator:

William L. Stone
4234398762
stone@etsu.edu

Business Contact:

William Stone
4234398762
BILLSTON@BIOINVENTIONSLLC.COM
Small Business Information at Submission:

BIOINVENTIONS, LLC
BIOINVENTIONS, LLC 2109 W MARKET ST, STE 120 JOHNSON CITY, TN 37604

EIN/Tax ID: 542106257
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
EAST TENNESSEE STATE UNIVERSITY
EAST TENNESSEE STATE UNIVERSITY
Johnson City, TN 37601
RI Type: Nonprofit college or university